BioCentury | Jan 18, 2016
Company News

Tensha Therapeutics, Roche deal

...million in cash plus up to $420 million in undisclosed clinical and regulatory milestones. Tensha’s TEN-010...
BioCentury | Jan 12, 2016
Company News

Roche BETs on Tensha

...front. Tensha shareholders are eligible for $420 million in milestones. The pharma will gain Tensha's TEN-010...
...NUT midline carcinoma (NMC); and one in acute myelogenous leukemia (AML) and myelodysplastic syndromes (MDS). TEN-010...
...see BioCentury, Sept. 12, 2011) . In November, Tensha presented the first clinical data for TEN-010...
BioCentury | Jan 5, 2015
Product Development

BETting early

...Tensha Therapeutics Inc. 's TEN-010 is in trials in solid tumors, and AML and MDS. TEN-010...
BioCentury | Oct 30, 2014
Cover Story

Redistributing BRD4 in inflammation

...Cancer Institute and founder of Tensha Therapeutics Inc. , which has the BET bromodomain inhibitor TEN-010...
BioCentury | Oct 9, 2014
Distillery Therapeutics

Indication: Various

...BET bromodomain proteins, has completed Phase II trials to treat atherosclerosis. Tensha Therapeutics Inc. has TEN-010...
BioCentury | Jul 31, 2014
Targets & Mechanisms

Taking a BET on hedgehog

...not respond to requests for comment. Tensha has the JQ1-derived small molecule BET bromodomain inhibitor TEN-010...
BioCentury | Jul 24, 2014
Distillery Therapeutics

Indication: Cancer

...development for various cancers. Tensha Therapeutics Inc. has the JQ1-derived small molecule BET bromodomain inhibitor TEN-010...
BioCentury | May 15, 2014
Cover Story

Chromatin's rising tide

...five BET bromodomain inhibitors are now in the clinic ( see Table 1). These include TEN-010...
...Tanabe Pharma Corp. (Tokyo:4508) OTX015 BET bromodomain inhibitor Hematologic malignancies Phase I Tensha Therapeutics Inc. TEN-010...
BioCentury | Apr 17, 2014

Expanding into new (bromo)domains

...molecule inhibitor of BRD2, BRD3 and BRD4 Phase I for hematological malignancies Tensha Therapeutics Inc. TEN-010...
BioCentury | Sep 5, 2013
Distillery Therapeutics

Indication: Cardiovascular disease

...additional animal models. Tensha Therapeutics Inc., cofounded by James Bradner, has the BET bromodomain inhibitor TEN-010...
Items per page:
1 - 10 of 12